CCNE1 Antibody
Shipped with Ice Packs 
In Stock 
Description
Definition and Biological Role of CCNE1 Antibody
CCNE1 antibodies are immunological reagents designed to bind specifically to the Cyclin E1 protein, a key regulator of the G1-to-S phase transition in the cell cycle. CCNE1 forms a complex with CDK2 to initiate DNA replication and cell division . These antibodies are used in techniques such as:
-
Western blotting (WB)
-
Immunohistochemistry (IHC-P)
-
Flow cytometry
-
Immunofluorescence (IF)
Key features of validated CCNE1 antibodies:
| Antibody Name | Host Species | Applications | Specificity Confirmed By |
|---|---|---|---|
| Anti-CCNE1 [CCNE1/2460] | Mouse | WB, IHC-P | HuProt protein array |
| 11554-1-AP | Rabbit | WB, IHC, IP | U2OS/MDA-MB-231 cells |
Mechanistic Insights into CCNE1 Function
CCNE1 overexpression drives uncontrolled cell proliferation by:
-
Promoting premature S-phase entry, leading to genomic instability
-
Enhancing epithelial-mesenchymal transition (EMT) and metastasis
Studies using CCNE1 antibodies have revealed its interaction with CDK2 and its role in activating the MMB–FOXM1 mitotic transcriptional program, which accelerates cell division .
Cancer Prognosis
-
Overexpression correlates with poor survival in breast (BRCA), lung (LUAD), liver (LIHC), and ovarian cancers .
-
Immune microenvironment modulation: High CCNE1 levels associate with increased cancer-associated fibroblasts in BRCA, COAD, and STAD tumors .
Therapeutic Targeting
Pathological Response Prediction
-
CCNE1 immunohistochemistry does not predict taxane-platinum chemoresistance in ovarian cancer, challenging earlier hypotheses .
Immune Correlations
-
CCNE1 expression positively correlates with TMB, MSI, and immune checkpoint markers (e.g., PD-1, CTLA-4), suggesting immunotherapy implications .
Preclinical Models
-
Xenograft studies: RP-6306 (PKMYT1 inhibitor) achieves 84% tumor regression in CCNE1-amplified OVCAR3 models .
-
Patient-derived organoids: CCNE1 amplification sensitizes tumors to CDK1-targeted therapies .
Validation Metrics
Limitations and Future Directions
Product Specs
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. Store at -20°C. Avoid freeze/thaw cycles.
Lead Time
Typically, we can ship products within 1-3 business days after receiving your order. Delivery times may vary depending on the purchase method or location. Please consult your local distributors for specific delivery time information.
Synonyms
CCNE antibody; Ccne1 antibody; CCNE1_HUMAN antibody; cyclin E variant ex5del antibody; cyclin E variant ex7del antibody; Cyclin E1 antibody; Cyclin Es antibody; Cyclin Et antibody; CyclinE antibody; G1/S specific cyclin E antibody; G1/S-specific cyclin-E1 antibody
Target Names
Uniprot No.
Target Background
Function
CCNE1 Antibody is essential for the control of the cell cycle at the G1/S (start) transition.
Gene References Into Functions
- miR-874 inhibits CCNE1 expression during growth factor deprivation, and its downregulation in osteosarcomas leads to CCNE1 upregulation and more aggressive growth phenotypes. PMID: 29109143
- Amplified/cyclin E1(hi) and non-amplified/cyclin E1(hi) tumors exhibit distinct pathological and biological characteristics as well as clinical outcomes, suggesting they are separate subsets of cyclin E1(hi) HGSOC. PMID: 30209015
- Breast cancer recurrence-free interval was significantly worse in patients with cyclin E (LMW-E)-positive tumors receiving aromatase inhibitor (AI) neoadjuvant therapy compared to those with LMW-E negative tumors. PMID: 28947566
- In a series of human biopsies, non-metastatic SCCs displayed a higher degree of chromosomal alterations and increased expression of the S phase regulator Cyclin E and the DNA damage signal gammaH2AX than the less aggressive, non-squamous, basal cell carcinomas. However, metastatic Squamous cell carcinoma lost the gammaH2AX signal and Cyclin E, or accumulated cytoplasmic Cyclin E. PMID: 28661481
- Cytoplasmic cyclin E identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes. These patients may benefit from alternative therapies targeting the oncogenic isoforms of cyclin E. PMID: 27881578
- Our findings validate the assumption that CBX7 is a tumor suppressor of gliomas. Furthermore, CBX7 serves as a potential and novel prognostic biomarker in glioma patients. We also elucidated that CBX7 silences CCNE1 through a combination of CCNE1 promoter and the recruitment of HDAC2. PMID: 28460453
- Our findings suggest that gene copy-number gain and upregulation of CCNE1 occur in ovarian clear cell carcinoma and are associated with a worse clinical outcome, influencing the survival of early-stage patients. PMID: 27767100
- YAP/TAZ pathways contribute to the proliferation/quiescence switch during colon cancer 5FU treatment based on the concerted regulation of Cyclin E1 and CREB. PMID: 27527859
- Silencing of CDCA5 suppresses proliferation of gastric cancer cells by inducing G1-phase arrest via downregulating CCNE1. Overexpression of CDCA2, conversely, promotes LAC cells proliferation by upregulating CCNE1. PMID: 29326043
- Analysis of genomic data from TCGA demonstrated coamplification of CCNE1 and AKT2. Overexpression of Cyclin E1 and AKT isoforms, along with mutant TP53, conferred malignant characteristics in untransformed fallopian tube secretory cells, the dominant site of origin of high-grade serous ovarian cancer. PMID: 27663592
- Findings suggest that amplification of CCNE1 serves as one mechanism for the development of some serous tubal intraepithelial carcinomas. PMID: 27443516
- Prognostic gene sets based on 13 genes were developed and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts. PMID: 28082741
- Cyclin E1 mRNA and protein expressions were suppressed. PMID: 26603262
- The opposing effects of ORC1 (represor) and CDC6 (gene activator) in controlling the level of Cyclin E ensures genome stability and a mechanism for linking directly DNA replication and cell division commitment. PMID: 27458800
- High cyclin E expression is associated with breast cancer. PMID: 28760857
- High CCNC1 expression is associated with inflammatory breast cancer. PMID: 28107181
- Inhibition of cell division cycle associated 2 (CDCA2) suppressed the proliferation of lung adenocarcinoma (LAC) cells via G1 phase arrest by downregulating cyclin E1(CCNE1), while overexpression of CDCA2 promoted LAC cells proliferation by upregulating CCNE1. PMID: 28423619
- A PI3K/PKCiota/cyclin E signaling pathway serves as a therapeutic target during ovarian tumorigenesis. PMID: 26279297
- Amplification of 19q12 CCNE1/URI was found in 10.4% (28/270) and was significantly associated with type II endometrial cancer (EC) high grade, advanced FIGO stage, and aberrant tumor supressor p53 expression. PMID: 27582547
- Results show that cyclin E1 and CDK2 participate in STC1 promoting cell proliferation of prostate neoplasm cells. PMID: 28350121
- Cyclin E is specifically dephosphorylated at S384 by the PP2A-B56 phosphatase, thereby uncoupling cyclin E degradation from cyclin E-CDK2 activity. PMID: 28137908
- These results provide evidence that ARTD1 regulates cell cycle re-entry and G1/S progression via cyclin E expression and p27(Kip 1) stability independently of its enzymatic activity, uncovering a novel cell cycle regulatory mechanism. PMID: 27295004
- These results demonstrate a repressor role for NFAT1 in cell cycle progression and Cyclin E expression in B lymphocytes, suggesting a potential function for NFAT1 protein in B cell malignancies. PMID: 27399331
- High CCNE1 amplification and expression is associated with breast cancer. PMID: 26810187
- CCNE1/REL gene interaction may play pivotal roles in the occurrence and development of Postmenopausal Osteoporosis. PMID: 26676054
- These results indicate that miR-25 has anti-apoptosis roles in AGS cells, possibly via inhibiting FBXW7 and thus promoting oncogenes, such as CCNE1 and MYC. PMID: 27120728
- Cyclin E-driven OvCa cells appeared addicted to glucose metabolism via TCA. Combined CDKi with modalities targeting TCA, like SDHA inhibition, showed promising effects for this genotype. Combined blockade of CDK and SDH, both genetically and pharmaceutically, showed synergy and resulted in inhibited proliferation, migration, invasion, and migration in A2780 cells. PMID: 26826064
- Over-expression of CCNE1 is associated with non-small cell lung cancer. PMID: 26771237
- High levels of cyclin E are a predictor of poor prognosis among patients with gastrointestinal cancer. [meta-analysis] PMID: 25627202
- The effects of CCNE1 knockdown were dependent on the CCNE1 expression status. PMID: 26647729
- Data show that melanoma antigen, family C, 2 protein (MAGE-C2) binds with RING-box protein 1 (Rbx1) and Cullin 1, and regulates cyclin E stability in melanoma cells. PMID: 26540345
- The findings suggest that the role of cyclin E and tumor specific low molecular weight isoforms as mediators of tumorigenesis is in part dependent on p53 context. PMID: 26625764
- Ad-cycE can target cyclin E overexpression in cancer cells and repress tumor growth in syngeneic mouse models. PMID: 26475304
- Ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy. PMID: 26204491
- Our findings identify a novel mechanism of cyclin E-mediated Mcl-1 regulation in human cancer. PMID: 26219338
- miR-15b might be involved in termination of osteoblastic cells proliferation by arresting them at G0/G1 phase through direct targeting cyclin E1. PMID: 26007664
- A significant correlation between cyclin E1 amplification and deletions at a number of the genomic loci in breast cancer. PMID: 25959964
- These results indicate that cyclin E1 is downregulated by both miR-497 and miR-34a, which synergistically retard the growth of human lung cancer cells. PMID: 25909221
- MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. PMID: 25732226
- Results show that miR-16 and HuR co-regulate the cyclin E1 mRNA without influencing each other's binding or expression. miR-16 regulation predominates, blocking upregulation of cyclin E1 by HuR. PMID: 25830480
- Expression of Notch1, -2, and -3, CDK2, and CCNE1 was significantly decreased by upregulation of ALDH1A1 in A549 cells, but increased by its interruption in A549s cells. PMID: 24671051
- Results show that CCNE1 and BRD4 on chromosome 19 were amplified/overexpressed in a substantial number of cases of epithelial ovarian cancer with no involvement of BRCA genes. PMID: 25892415
- This study indicates that CCNE1 rs1406 polymorphism may contribute to BC risk. PMID: 25159285
- Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA. PMID: 25399696
- miR-144-5p functions as a tumor suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of bladder cancer patients. PMID: 26057453
- HOXA7 promotes cell proliferation, and these changes are mediated by cyclin E1/CDK2. PMID: 25501982
- Aurora-A/HURP relays cell transforming signal to NF-kappaB, and the HURP/NF-kappaB complex is engaged in the regulation of cyclin E1 expression. PMID: 25289861
- Contrary to previous literature, we found a correlation between cyclin E expression and prognosis. Further large-scale studies are required to confirm our findings. PMID: 26026100
- Global gene expression profiling identifies ALDH2, CCNE1, and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. PMID: 25408144
- The cell cycle-associated proteins cyclin E and p27kip1 may have contributed to this antitumor effect. PMID: 25310086
Database Links
Protein Families
Cyclin family, Cyclin E subfamily
Subcellular Location
Nucleus.
Tissue Specificity
Highly expressed in testis and placenta. Low levels in bronchial epithelial cells.
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
